



MyoKardia to Participate in September Investor Conferences

August 28, 2019

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced its participation in the following upcoming investor conferences:

- **Citi 14th Annual Biotech Conference** in Boston, MA on Wednesday, September 4, 2019.
- **2019 Wells Fargo Healthcare Conference** in Boston, MA on Thursday, September 5, 2019. Taylor Harris, Chief Financial Officer, will present a corporate overview at 1:55 p.m. ET.
- **Morgan Stanley 17th Annual Global Healthcare Conference** in New York, NY on Tuesday, September 10, 2019. Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at 8:35 a.m. ET.
- **Bank of America Merrill Lynch Global Healthcare Conference 2019** in London, England on September 18, 2019.

Webcasts of the Wells Fargo and Morgan Stanley presentations will be available by visiting the Investors section of MyoKardia's website at <http://investors.myokardia.com>. A replay of the webcasts will be available on the MyoKardia website for 90 days following the conferences.

About MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious cardiovascular diseases. MyoKardia's initial focus is on the development of small molecule therapeutics aimed at the muscle proteins of the heart that modulate cardiac muscle contraction and underlying diseases of systolic and diastolic dysfunction. MyoKardia applies a precision medicine approach to develop its therapeutic candidates for patient populations with shared characteristics, such as causal genetic mutations or disease subtypes. MyoKardia has discovered a pipeline of product candidates directed at diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly 461) in Phase 3 and Phase 2 clinical trials for hypertrophic cardiomyopathies (HCM); MYK-491 in Phase 2 for patients with stable heart failure; and MYK-224, in Phase 1 development for HCM.

MyoKardia's mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

Contacts:

Michelle Corral
Corporate Communications & Investor Relations
MyoKardia, Inc.
650-351-4690
mcorral@myokardia.com

Hannah Deresiewicz (investors)
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com



Source: MyoKardia, Inc.